Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026
Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026
Company Deals

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Fineline Cube Apr 7, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026
Company

Viatris to Divest Women’s Health and API Businesses, Offloading 12 Factories and 6,000 Employees

Fineline Cube Oct 8, 2023

US-based Viatris Inc. (NASDAQ: VTRS) is set to divest its women’s health business, API operations...

Company Deals

Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine

Fineline Cube Oct 7, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic...

Company Drug

Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results

Fineline Cube Oct 7, 2023

Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor...

Company Deals

Kyowa Hakko Kirin to Acquire Orchard Therapeutics for $477.6 Million

Fineline Cube Oct 7, 2023

Japan-based Kyowa Hakko Kirin is poised to acquire UK-headquartered Orchard Therapeutics plc for a total...

Company Deals

PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development

Fineline Cube Oct 7, 2023

Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...

Company Deals

Boehringer Ingelheim Collaborates with Zeiss Medical Technology on Retinal Disease Detection

Fineline Cube Oct 7, 2023

Germany’s Boehringer Ingelheim (BI) has entered into a collaboration agreement with fellow German firm Zeiss...

Policy / Regulatory

Guangdong Medicine Exchange Announces Volume-Based Procurement for Medical Devices

Fineline Cube Oct 7, 2023

The Guangdong Medicine Exchange has issued three notifications regarding the volume-based procurement (VBP) of medical...

Deals Medical Device

Cardinal Health Acquires MedAlliance for $1.135 Billion to Enhance Vascular Intervention Portfolio

Fineline Cube Oct 7, 2023

US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a...

Company Deals

Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation

Fineline Cube Oct 7, 2023

The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements...

Company Drug

Everest Medicines and Calliditas Present New Data on Nefecon for IgA Nephropathy

Fineline Cube Oct 7, 2023

Everest Medicines (HKG: 1952), in partnership with Calliditas Therapeutics AB (Nasdaq: CALT), recently presented new...

Company Drug

Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine

Fineline Cube Oct 7, 2023

Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...

Company Drug

Amicus Therapeutics Secures FDA Approval for Pombiliti and Opfolda Combination Therapy

Fineline Cube Oct 7, 2023

Amicus Therapeutics (NASDAQ: FOLD), headquartered in the United States, has announced that it has received...

Company Deals

Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan

Fineline Cube Oct 7, 2023

Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...

Company Drug

Transcenta Secures FDA Approval for Phase III Trial of Osemitamab

Fineline Cube Oct 7, 2023

China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...

Policy / Regulatory

Shanghai Boosts Community Healthcare with Enhanced Reimbursement and Services

Fineline Cube Sep 28, 2023

Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...

Company Deals

Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases

Fineline Cube Sep 28, 2023

Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...

Company Deals

Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates

Fineline Cube Sep 28, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop,...

Company Drug

Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy

Fineline Cube Sep 28, 2023

The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...

Company Medical Device

Neusoft Medical’s NeuRT Aurora Receives NMPA Approval for Advanced Radiotherapy Platform

Fineline Cube Sep 28, 2023

Neusoft Medical Systems Co., Ltd, a leading player in the medical technology sector, has announced...

Company Medical Device

CStone Pharmaceuticals’ PDGFRA Mutation Detection Kit Receives NMPA Approval

Fineline Cube Sep 28, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received marketing...

Posts pagination

1 … 446 447 448 … 647

Recent updates

  • Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications
  • Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data
  • Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders
  • Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis
  • Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Others

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Company Drug

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.